1 enrolling by invitation. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Enrolling by invitation 1 |
Follow Rondo Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 RNDO-564, Pembrolizumab - Non Small Cell Lung Cancer, Cervical Cancer | Phase 1 | Enrolling by invitation | Rondo Therapeutics | 149 | 2025-11-17 | 2026-06-11 |
Adenocarcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Esophageal Squamous Cell Carcinoma (1) · Neoplasms (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1) · Urinary Bladder Neoplasms (1) · Uterine Cervical Neoplasms (1)
pembrolizumab (1)
United States (1)